



23 November 2004

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

\$1 Million Placement to Fund First Stage FerriScan™ Rollout

Perth, Australia, Tuesday 23 November 2004: The Board of Resonance Health Limited (ASX:RHT) is pleased to announce the completion of a placement of 7,970,000 Ordinary fully paid shares at 13.5 cents each and 7,970,000 RHTOB Options exercisable at \$0.40 each (subject to shareholder approval) to professional investors in accordance with Section 708 of the Corporations Act.

Details of the placement are contained in the attached Appendix 3B, however by way of summary explanation, the Company has placed 7,970,000 Ordinary shares (being 15% of its pre-existing Ordinary share capital) with professional investors at 13.5 cents each to raise a net total of \$1,022,153 (after 5.00% brokerage costs) for the Company. The proceeds of the placement will be utilised to provide funding to its 51% subsidiary, Inner Vision Biometrics Pty Ltd (IVB) in order to facilitate the rollout of the FerriScan™ liver iron scan technology in Australia and the U.K. after the test is listed by the Therapeutic Goods Administration (TGA) in Australia and therefore access is gained to European markets with CE Mark certification.

Funding will also be provided to match those recently announced as being offered by the Australian Government's BIF Grant to develop the FerriScan™ technology platform for expanded uses as a non-invasive test for liver cirrhosis and fibrosis using magnetic resonance imaging (MRI). This has the potential to open a significantly broader market segment given the extensive unmet need for non-invasive monitoring of fibrosis in patients with a range of progressive liver diseases, including hepatitis C. In the US alone, more than 4 million people are infected with hepatitis C.

In addition to the placement of the above Ordinary shares, the placement recipients, subject to shareholder approval will receive a one for one free entitlement to a RHTOB Option. The terms of these Options are the same as the existing quoted RHTOB Options, being an exercise price of 40 cents per Ordinary share with an expiry date of 15 January 2008. A shareholder meeting will be called as soon as practicable to vote on the issue of these Options.

Following the placement and final receipt of funds from current option exercises (**due by 8 December 2004**), the Company expects to be in a strong cash position to meet its funding commitments to IVB on a timely basis and to assist IVB in accelerating its commercialisation objectives for the FerriScan™ technology.

END OF LETTER – APPENDIX 3 B FOLLOWS

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Resonance Health Limited

ABN

96 006 762 492

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | |
|--|---|
| 1 +Class of +securities issued or to be issued | Ordinary

Options – 40 cents on or before 15/1/2008 |
| 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued | 7,970,000 ordinary shares - Quoted

7,970,000 options – 40 cents on or before 15/1/2008 – Quoted
(ASX Code: RHTOB) |

+ See chapter 19 for defined terms.

<p>3 Principal terms of the ⁺securities (eg, if options, exercise price and expiry date; if partly paid ⁺securities, the amount outstanding and due dates for payment; if ⁺convertible securities, the conversion price and dates for conversion)</p>	<p>Options – exercisable at 40 cents on or before 15/1/2008 which entitles the holder to subscribe for one Resonance Health Ltd ordinary share upon payment of 40 cents per option.</p>
<p>4 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>Ordinary – yes</p> <p>Options – only on exercise</p>
<p>5 Issue price or consideration</p>	<p>Ordinary - \$1,075,950</p> <p>Options – nil</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Share placement with professional investors to provide funding to its 51% controlled subsidiary, Inner Vision Biometrics Pty Ltd in order to facilitate the rollout of the FerriScan liver iron scan technology in Australia and the U.K. upon TGA and CE mark registration.</p> <p>Funding will also be provided for the development of FibroScan which uses the FerriScan technology platform to broaden the scope of the liver iron scan to include an analysis of liver fibrosis.</p>
<p>7 Dates of entering ⁺securities into uncertificated holdings or despatch of certificates</p>	<p>9 December 2004</p>

8	Number and ⁺ class of all ⁺ securities quoted on ASX (including the securities in clause 2 if applicable)	Number	⁺ Class
		86,514,543	Ordinary
		53,000,351	Options – 15 cents on or before 15/1/07
		11,766,152	Options – 40 cents on or before 15/1/08
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (including the securities in clause 2 if applicable)	Number	⁺ Class
		800,000	Options – 40 cents on or before 07/7/09
		1,600,000	Options – 30 cents on or before 07/7/09
		300,000	Options – 10 cents on or before 15/1/07
		24,000,000	IVBH Incentive shares <u>IVBH Incentive options</u>
		10,000,000	Options – 20 cents, 3 years from date of issue
		10,000,000	Options – 30 cents, 3 years from date of issue
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable	

+ See chapter 19 for defined terms.

Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or non-renounceable?
- 13 Ratio in which the +securities will be offered
- 14 +Class of +securities to which the offer relates
- 15 +Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions
- 18 Names of countries in which the entity has +security holders who will not be sent new issue documents
- Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7.
- 19 Closing date for receipt of acceptances or renunciations

- | | | |
|----|---|--|
| 20 | Names of any underwriters | |
| 21 | Amount of any underwriting fee or commission | |
| 22 | Names of any brokers to the issue | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders | |
| 25 | If the issue is contingent on +security holders' approval, the date of the meeting | |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 28 | Date rights trading will begin (if applicable) | |
| 29 | Date rights trading will end (if applicable) | |
| 30 | How do +security holders sell their entitlements <i>in full</i> through a broker? | |
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | |

+ See chapter 19 for defined terms.

32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which +quotation is sought	
39	Class of +securities for which quotation is sought	
40	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: <ul style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	

+ See chapter 19 for defined terms.

Number and +class of all +securities quoted on ASX (including the securities in clause 38)

Number	+Class

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Stuart Usher
Joint Company Secretary

23 November 2004

+ See chapter 19 for defined terms.